Advanced risk signature analysis of inflammation markers in predicting prostate cancer using the Swedish Apolipoprotein-related MOrtality RISk (AMORIS) cohort
Authors:
- G. GeorgeGGG. George
- M. RowleyMRM. Rowley
- A.C.C. CoolenACA.C.C. Coolen
- A. Santa OlallaAOA. Santa Olalla
- N. HammarNHN. Hammar
- M. FeychtingMFM. Feychting
- S.N. KaragiannisSKS.N. Karagiannis
- D. EntingDED. Enting
- M. Van HemelrijckMHM. Van Hemelrijck
Open Access
- 3 June 2025
- journal article
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 8
Abstract
No abstract availableKeywords
Funding Information
- Cancer Research UK (C45074/A26553)
This publication has 28 references indexed in Scilit:
- Association between autoimmunity-related disorders and prostate cancer: A Mendelian randomization studyCancer Pathogenesis and Therapy, 2024
- Genetic Risk, Lifestyle, and Age-Related Macular Degeneration in EuropeOphthalmology, 2021
- How Comorbidities Shape Cancer Biology and SurvivalTrends in Cancer, 2021
- Serum inflammatory markers in relation to prostate cancer severity and death in the Swedish AMORIS studyInternational Journal of Cancer, 2018
- Histological scoring of immune and stromal features in breast and axillary lymph nodes is prognostic for distant metastasis in lymph node‐positive breast cancersThe Journal of Pathology: Clinical Research, 2018
- A latent class model for competing risksStatistics in Medicine, 2017
- The elevated C-reactive protein level is associated with poor prognosis in prostate cancer patients treated with radiotherapyEuropean Journal of Cancer, 2015
- The Role of Inflammation in Prostate Cancer2014
- Prediagnostic circulating markers of inflammation and risk of prostate cancerInternational Journal of Cancer, 2013
- Risk of prostate cancer is not associated with levels of C‐reactive protein and other commonly used markers of inflammationInternational Journal of Cancer, 2010